Back to search

Switzerland· 53677004

Nimbex 20mg/10ml, Injektionslösung

A cisatracurium product, registered in Switzerland by Aspen Pharma Schweiz GmbH and dispensed under Swissmedic category B. The same ATC class is registered in 15 of our 19 countries.

Cat B (Swissmedic)ATC M03AC11

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · CHPublic registernormalisedNimbex 20mg/10ml, InjektionslösungATCM03AC11REGISTER NO.53677004PACKS LISTED0CHECKEDJune 26, 2026

Where it is registered

Cisatracurium is registered in 15 of 19 countries.

Countries holding a registration under ATC M03AC11 (cisatracurium), each read from that country’s own register.

  • This record: Switzerland
  • 8 of them publish a price we can compare per daily dose

Cisatracurium · ATC M03AC11

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Manufacturer
Aspen Pharma Schweiz GmbH
Country
Switzerland (CH)
ATC code
M03AC11
ATC class
Cisatracurium
Defined daily dose
10.5 mg, P
Swissmedic category
B
Reimbursed
No
Last checked
June 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

89 interactions on record for cisatracurium.

Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cisatracurium · interactions on record

89 records

  • 12 severe
  • 44 moderate
  • 4 minor
  • 29 info

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • ParomomycinA07AA06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ba78e871-828b-4c44-8a9e-8589f425dde4
GET /v1/drugs/ba78e871-828b-4c44-8a9e-8589f425dde4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}

See everything about cisatracurium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.